Phase II clinical trial - Appareil pulmonaire
AMG20200491 - DeLLPhi-301
Appareil pulmonaire
Essai clinique fermé
Public cible
Adulte
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment.
Description de l'essai
The main aim of this study is to:;Àevaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of Tarlatamab for Part 1 only;Àevaluate anti-tumor activity of Tarlatamab as determined by objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2
Liens utiles
PAULINE DU RUSQUEC
Investigateur principal